Carcinoma Clinical Trial
Official title:
Family Home Care for Cancer - A Community-Based Model
| Verified date | December 2011 |
| Source | Michigan State University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
Patients with advanced cancer who are undergoing chemotherapy and who report pain and
fatigue at intake in the past 24 hours or at a level 2 or higher of pain or fatigue at a 3
or higher on a 10-point scale will be assigned randomly to an 8-week, 6-contact self
management attention control (SMAC) intervention, or to a 8-week, 6-contact experimental
patient intervention for management of symptoms and support (PIMSS) targeted toward symptom
management, reducing impact on physical role and social functioning and emotional distress.
Both groups will continue to receive conventional cancer care.
When compared with the self-management attention control intervention, patients exposed to
the experimental intervention will report statistically significant positive effects on the
following:
1. The primary outcome--total number of symptoms reported;
2. The secondary patient outcomes--reduced deterioration in physical role impact and
social functioning, emotional distress, levels of communication with caregiver about
care, and communication and satisfaction with provider care; and
3. Caregiver outcomes--greater involvement in symptom management, increased mastery of the
caregiving process, reduced levels of depression and burden.
| Status | Completed |
| Enrollment | 350 |
| Est. completion date | October 2006 |
| Est. primary completion date | October 2006 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 21 Years and older |
| Eligibility |
Inclusion Criteria: - 21 years of age or older - solid tumor cancer diagnosis - receiving chemotherapy treatment - advanced cancer - family caregiver Exclusion Criteria - Emotional or psychology disorder for which patient is receiving treatment - does not speak English - does not have access to a telephone - difficulty hearing on the telephone |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Country | Name | City | State |
|---|---|---|---|
| United States | Michigan State University | East Lansing | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| Michigan State University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Primary patient outcome | Lower reported severity of symptoms | ||
| Secondary | Secondary Patient Outcomes | Reduced deterioration in physical role impact and social functioning, emotional distress, levels of communication with caregiver about care and communication, and satisfaction with provider care |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05283226 -
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT04362072 -
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
|
Phase 4 | |
| Completed |
NCT04033991 -
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
|
||
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01942200 -
A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
|
||
| Completed |
NCT01061645 -
Study of MOC31-PE in Antigen Positive Carcinomas
|
Phase 1 | |
| Completed |
NCT00532155 -
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT00557596 -
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00216372 -
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
|
Phase 3 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
| Recruiting |
NCT05752357 -
The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
|
||
| Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
| Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
| Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06112041 -
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
|
Phase 2 | |
| Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
| Recruiting |
NCT06013111 -
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
|
Phase 1 |